Biocon to enter hospital infections treatment segment

17 Aug 2010 Evaluate

Biotechnology firm Biocon is foraying into the critical care segment aiming to provide treatment for hospital infections, including post surgical complications and trauma. There is a perceptible increase in hospital acquired infections with respect to critical care illnesses in India.

This often requires treatment with anti-infectives. Biocon's comprehensive care division has been set up to counter this growing challenge by providing affordable and specialised solutions to such patients. The company will introduce five new products in the initial phase of launch for the treatment of critical illnesses like septicemia and other acute hospital infections.

The new comprehensive care division will be the fifth division for the company, complementing the existing product portfolios in diabetology, oncology, nephrology and cardiology divisions.

crackcrack

Biocon Share Price

304.00 5.15 (1.72%)
10-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1505.20
Dr. Reddys Lab 5922.45
Cipla 1339.45
Zydus Lifesciences 983.05
Lupin 1609.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.